Watson Pharmaceuticals, a specialty pharmaceutical company, has received FDA approval of an oral contraceptive product, a low dose oral contraceptive to combine 0.8mg norethindrone and 0.025mg ethinyl estradiol in chewable form, with four 75mg ferrous fumarate, or iron, placebo tablets.
Watson Pharmaceuticals receives FDA approval for oral contraceptive product